| CANTA Stock | | | SEK 1.84 0.03 1.66% |
Director
Dr. Patricia Delaite was Director of CANTARGIA AB since November 27, 2017. She is Medical Doctor and holds an MBA from University of Lausanne. She is presently Executive Medical director at Incyte Biosciences International in Geneva and has previously held leading positions at Ariad Pharmaceutical, Novartis and Eli Lilly, among others. since 2017.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 46 4 62 75 62 60 |
| Web | https://www.cantargia.com |
Cantargia Management Efficiency
The company has return on total asset
(ROA) of
(0.3963) % which means that it has lost $0.3963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.6913) %, meaning that it generated substantial loss on money invested by shareholders. Cantargia's management efficiency ratios could be used to measure how well Cantargia manages its routine affairs as well as how well it operates its assets and liabilities.
Cantargia AB , a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Cantargia AB was founded in 2010 and is based in Lund, Sweden. Cantargia operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 19 people. Cantargia AB (CANTA) is traded on Stockholm Exchange in Sweden and employs 27 people.
Management Performance
Cantargia AB Leadership Team
Elected by the shareholders, the Cantargia's board of directors comprises two types of representatives: Cantargia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cantargia. The board's role is to monitor Cantargia's management team and ensure that shareholders' interests are well served. Cantargia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cantargia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karin Leandersson, Director | |
| Magnus Persson, Chairman of the Board | |
| Dominique Tersago, Chief Officer | |
| Liselotte Larsson, Vice President - Operations | |
| David Liberg, Vice President Cancer Research | |
| Kjell Sjstrm, Founder | |
| Johanna Christensen, Financial Controller | |
| Goran Forsberg, Chief Executive Officer | |
| Nina Valkama, Exec Fin | |
| Bengt Jondell, Chief Financial Officer | |
| Adnan Deronic, IP Mang | |
| Lars Thorsson, Vice President Clinical Development | |
| Ignacio GarciaRibas, Chief Medical Officer | |
| Susanne Lagerlund, Vice President - Regulatory Affairs | |
| Thoas MD, Founder Director | |
| Marcuss, Founder Advisor | |
| Anders MartinLof, Director | |
| Thoas Fioretos, Director | |
| Patricia Delaite, Director | |
| Claus Andersson, Director | |
| Peter Madsen, Vice President - CMC | |
Cantargia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cantargia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Cantargia Stock Analysis
When running Cantargia's price analysis, check to
measure Cantargia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cantargia is operating at the current time. Most of Cantargia's value examination focuses on studying past and present price action to
predict the probability of Cantargia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cantargia's price. Additionally, you may evaluate how the addition of Cantargia to your portfolios can decrease your overall portfolio volatility.